Mycobiota-host immune interactions in IBD: coming out of the shadows

2021 has been a productive year for fungal research. Key studies focused on intestinal inflammation and inflammatory bowel disease highlight antibody-mediated immunity in control of fungal commensalism, commensal and dietary fungi in intestinal inflammation and wound healing, and the therapeutic pot...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Gastroenterology & hepatology 2022-02, Vol.19 (2), p.91-92
Main Author: Iliev, Iliyan D
Format: Article
Language:English
Subjects:
Colitis
Commensalism
Debaryomyces hansenii
Fungi - physiology
Gastrointestinal Microbiome - physiology
Host Microbial Interactions - immunology
Humans
Immunoglobulin A
Inflammation
Inflammatory bowel diseases
Inflammatory Bowel Diseases - diagnosis
Inflammatory Bowel Diseases - etiology
Inflammatory Bowel Diseases - therapy
Intestine
Macrophages
Wound healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:2021 has been a productive year for fungal research. Key studies focused on intestinal inflammation and inflammatory bowel disease highlight antibody-mediated immunity in control of fungal commensalism, commensal and dietary fungi in intestinal inflammation and wound healing, and the therapeutic potential of transgenic yeast engineered to sense and target factors during intestinal inflammation.Key advancesMycobiota-induced antibodies influence systemic antifungal immunity5 and fungal commensalism in the gut by targeting Candida albicans adhesins6 (Als3) and secreted virulence factors7 (candidalysin and Sap6). Targeting Als3 influenced the severity of colitis in mice6, whereas secretory IgA antibodies to candidalysin and Sap6 are dysregulated in Crohn’s disease7.Food-associated Candida species such as Debaryomyces hansenii can influence intestinal physiology1. D. hansenii found in mouse and human intestinal wounds prevent healing by turning protective macrophages into CCL5-producing perpetuators of tissue recovery1.Transgenic Saccharomyces cerevisiae were engineered to sense and respond to intestinal extracellular ATP and suppress intestinal inflammation in mouse models9, providing a powerful example of mycobiota-centred future therapeutics.
ISSN:1759-5045
1759-5053
DOI:10.1038/s41575-021-00541-2